Welcome to our dedicated page for Zai Lab SEC filings (Ticker: ZLAB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Zai Lab Limited filings document the SEC reporting record for its American depositary shares and the governance and financing disclosures of a Cayman Islands biopharmaceutical issuer. Form 8-K reports furnish quarterly and annual operating results, financial-condition updates and clinical or regulatory corporate updates tied to its oncology, immunology, neuroscience and infectious disease programs.
The filing record also includes proxy materials covering annual meeting matters, board governance, executive compensation and equity awards. Material-event reports describe capital-structure and liquidity matters, including working-capital credit arrangements, guarantees for Zai Lab Shanghai and related covenant disclosures, while ADR disclosures distinguish the SEC-registered depositary shares from ordinary shares listed in Hong Kong.
Zai Lab Ltd Chairperson and CEO Du Ying reported a series of bona fide gifts of American Depositary Shares (ADSs). On May 26 and 27, 2026, Du Ying gifted a total of 107,700 ADSs in three transactions to trusts established for the benefit of an adult son. Each ADS represents ten Ordinary Shares of the company. After these transfers, Du Ying continues to hold 1,158,583 ADSs directly, indicating a substantial remaining ownership position.
Zai Lab Limited reported a senior leadership change. The Board determined that Josh Smiley will cease serving as President and Chief Operating Officer effective May 18, 2026, with his last day of employment on May 22, 2026.
Responsibilities from these roles have been taken over by Board Chair, Founder and Chief Executive Officer Samantha Du and other members of the management team. Mr. Smiley will receive severance under his existing employment agreement, contingent on signing a customary release.
Zai Lab Ltd Chairperson & CEO Du Ying reported routine equity compensation activity involving American Depositary Shares (ADSs). On May 19, Du Ying exercised stock options to acquire 261,092 ADSs at an exercise price of $1.74 per ADS and simultaneously used 117,435 ADSs, valued at $18.75 per ADS, to satisfy tax obligations through a tax-withholding disposition. Following these transactions, Du Ying directly held 1,266,283 ADSs. Each ADS represents ten ordinary shares of Zai Lab, and the activity was carried out under a pre-arranged Rule 10b5-1 trading plan. The filing shows an exercise-and-hold pattern with part of the shares applied to taxes and no open-market sale.
Zai Lab Ltd Chairperson and CEO Du Ying reported option exercises and share sales in American Depositary Shares (ADS). On May 15 and May 18, Du Ying exercised stock options to acquire a total of 100,000 ADS at an exercise price of $1.74 per ADS and sold 100,000 ADS in open-market transactions.
The reported weighted average sale prices were $20.7422 and $18.9953 per ADS, with individual trades executed within disclosed price ranges. These trades were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on November 11, 2025. Following the transactions, Du Ying directly holds 1,122,626 ADS.
Ying Du proposes sale of American Depositary Shares. The filing lists multiple proposed dispositions of ADSs on various dates in 2026, with repeated entries of 50,000 shares at stated gross proceeds (examples include $958,155 and $1,034,110). The transactions are reported through a broker and noted as cash settlements.
Zai Lab Ltd Chief Legal Officer Edmondson Frazor Titus III reported an open-market sale of 3,517 American Depositary Shares (ADS) on May 14, 2026 at a price of $20.19 per ADS. Each ADS represents ten Ordinary Shares of Zai Lab.
Following the transaction, he directly holds 19,849 ADS. The sale was executed under a pre-arranged Rule 10b5-1 trading plan adopted on September 12, 2025, indicating the trade was scheduled in advance rather than timed discretionarily.
Zai Lab Ltd Chairperson and CEO Du Ying reported option exercises and share sales in American Depositary Shares (ADSs). On May 13–14, 2026, Du Ying exercised stock options to acquire 100,000 ADSs at a price of $1.74 per ADS equivalent, then sold 100,000 ADSs in open-market transactions at weighted average prices of $19.4432, $20.2223, and $20.0915 per ADS.
After these transactions, Du Ying directly holds 1,122,626 ADSs and 361,092 stock options outstanding. All trades were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on November 11, 2025, indicating the timing was set in advance rather than decided opportunistically.
ZLAB reported proposed sales of American Depositary Shares by an insider, listing multiple transactions and dates. The notice itemizes repeated proposed dispositions of 50,000 ADS lots on several dates and smaller dispositions (for example, 1,067 ADS on 03/11/2026). Transaction entries show trade dates, share counts and gross proceeds for each line item.
ZLAB insider reported proposed and completed sales of American Depositary Shares (ADS). The filing lists multiple ADS dispositions by Ying Du, including 50,000-share transactions dated 03/04/2026, 03/05/2026, 03/06/2026, 03/09/2026 and 05/13/2026. Several other smaller ADS sales are shown in March and April 2026.
ZLAB insider notice of proposed resale activity: multiple American Depositary Shares were listed as sold or to be sold under restricted stock vesting and compensation arrangements. The excerpt lists specific vesting entries of 550 ADS (04/03/2025) and 2,967 ADS (08/17/2025), and several sales by an individual during March–April 2026.